Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
This article was originally published in The Pink Sheet Daily
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
You may also be interested in...
Newron expects partner Zambon to start marketing safinamide in the first half of 2015 in Europe, and to resubmit it soon for U.S. approval. Other positive CHMP opinions this month include Orexigen’s obesity therapy Mysimba and Durata’s antibiotic Xydalba.
With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.
Italy's Newron aims to become a leading European CNS-focused biotech company with the proposed acquisition of Sweden's NeuroNova adding product candidates in ALS and Parkinson's disease to its portfolio.